Reduced plasma coagulation factor XIII in patients with acute leukemia in remission during consolidation chemotherapy cycles.
Ann Hematol
; 102(7): 1739-1744, 2023 Jul.
Article
em En
| MEDLINE
| ID: mdl-37160793
ABSTRACT
Acute leukemia (AL) is a malignancy from hematologic stem cells (HSC). Consolidation with intensive chemotherapy is required after induced remission and repeatedly causes treatment-related bleeding that is usually attributed to chemotherapy-induced thrombocytopenia (CIT). However, our previous study demonstrated that severe deficiency of plasma coagulation factor XIII (pFXIII) also participated in the bleeding of CIT in AL. However, the relationship between pFXIII deficiency and consolidation chemotherapy was unknown. Here, we observed the concentration of pFXIII in patients with AL before and after consolidation chemotherapy and reevaluated the correlation to bleeding in myelosuppression. Thus, we found that the concentration of pFXIII before chemotherapy in all patients was markedly lower than in the control data and was further decreased by chemotherapy, related to bleeding in myelosuppression. These findings indicated that chemotherapy-induced pFXIII deficiency should be of concern and explored in depth.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Doenças da Medula Óssea
/
Leucemia Mieloide Aguda
/
Deficiência do Fator XIII
/
Antineoplásicos
Limite:
Humans
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article